跳至主要内容
临床试验/NCT03408691
NCT03408691已完成不适用

The Effect of a Probiotic Strain on Stress-related Intestinal Hyperpermeability in Adult Humans.

Universitaire Ziekenhuizen KU Leuven2 个研究点 分布在 1 个国家目标入组 117 人开始时间: 2018年1月23日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
117
试验地点
2
主要终点
Lactulose-Mannitol Ratio (LMR) during the stress condition vs. baseline

研究概览

简要总结

This is a single-site exploratory study aiming to demonstrate the effect of a fresh fermented dairy drink containing a probiotic strain on stress-related intestinal hyperpermeability in students defending a bachelor's or master's thesis in front of a jury at the University of Leuven (Belgium).

详细描述

The study is conceived as a single-site exploratory study with a randomized, controlled, parallel group design. There will be a double blind with 2 intervention arms (Test product with probiotic and acidified milk Control) plus an extra open label arm without intervention in a 2:2:1 ratio. The goal of the open-label arm is to confirm our previous data on the effect of stress on small intestinal permeability (see reference), without powering the study to detect a significant difference within this open-label arm. The participants and the investigators are blinded to the allocation to the probiotic vs. acidified milk control arm. However, there is no blinding in the arm without intervention.

In vivo intestinal permeability and salivary markers of psychological stress and activation of the autonomous nervous system will be measured and questionnaires will be completed at 4 different test days: baseline (V2), two weeks after randomization (V3), during an oral defense of a master's or bachelor's thesis (V4) and finally after pretreatment with Indomethacin (V5).

The 5 study visits are organized around the thesis defence (D0):

V1 (screening + inclusion) takes place within 2 to 3 weeks prior to the randomization.

V2 (baseline + randomization) will take place between D-35 to D-27. V3 (randomization + 2 weeks) will take place at D-14 +/-1day. V4 (thesis defense) is D0 and organized by the University. V5 (Indomethacin) will take place at D+14 +/-1day.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

盲法说明

double blind only in Test and Control arm open label in arm without intervention

入排标准

年龄范围
20 Years 至 30 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Student defending a bachelor's or master's thesis in front of a jury
  • Age 20 till 30 years (both included), both genders
  • Subject, upon briefing of the content of the present study, fully understanding and agreeing to its objective and having given written (dated and signed) informed consent form to take part in the study
  • Subject willing to consume 2 units of investigational product per day during the investigational product consumption period.
  • For females: If of child bearing potential, female subjects must be using or complying with methods of contraception
  • Subject willing to strictly follow dietary/medication instructions for the entire duration of the study
  • Subject must have access to a refrigerator with adequate space to store the investigational products according to the labels' storage recommendations and a freezer for the cooling elements in the transport bag

排除标准

  • Subject with chronic gastrointestinal disorders or symptoms, type 1 or type 2 diabetes mellitus, psychiatric disease including but not limited to depression (screened by PHQ-9) and general anxiety disorder (screened by GAD-7), celiac disease, food allergy or a history of atopic conditions (eczema, allergic asthma, allergic rhinoconjunctivitis) requiring active treatment
  • Subject with allergy or intolerance to non-steroidal anti-inflammatory drugs (NSAID)
  • Subject with first degree relatives with coeliac disease, inflammatory bowel disease (IBD) or type 1 diabetes
  • Subject with known or suspected lactose intolerance or suspected allergy or hypersensitivity to any component of the study product(s) (e.g. milk protein)
  • Subject receiving (currently or in the 2 last weeks) systemic treatment or topical treatment likely to interfere with evaluation of the study parameters: antibiotics, intestinal or respiratory antiseptics, anti-rheumatics, NSAIDs and steroids prescribed in chronic inflammatory diseases.
  • Active smoker with at least 7 cigarettes per week
  • Subject consuming regularly (>1/week) more than 3 units of alcohol per day.

研究组 & 干预措施

Test product

Active Comparator

Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks

干预措施: Fresh fermented dairy drink containing probiotic strain (Dietary Supplement)

Control product

Placebo Comparator

Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks

干预措施: Acidified dairy drink without ferment (Other)

No product

No Intervention

no product

结局指标

主要结局

Lactulose-Mannitol Ratio (LMR) during the stress condition vs. baseline

时间窗: oral administration of Test or Control product for 4 weeks before stress condition

LMR or in vivo small intestinal permeability during stress condition vs. baseline in the Test product with probiotic compared to the acidified milk Control arm

次要结局

  • LMR during administration of Test or Control product vs. baseline(oral administration of Test or Control product for 2 weeks)
  • Subjective anxiety levels (STAI state) during the stress condition vs. baseline(oral administration of Test or Control product for 4 weeks before stress condition)
  • Salivary cortisol during the stress condition vs. baseline(oral administration of Test or Control product for 4 weeks before stress condition)
  • LMR after indomethacin vs. baseline(oral administration of Test or Control product for 6 weeks before indomethacin)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验